Navigation Links
The Quigley Corporation to Announce Second Quarter Results and Host Audio Web Cast
Date:7/30/2009

DOYLESTOWN, Pa., July 30 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com today announced it will issue its second quarter results before market open on Wednesday, August 5, 2009.

Ted Karkus, Chairman and CEO, will provide a Company overview including a review of recent activities and second quarter results on a conference call which will be web cast on The Quigley Corporation's web site, (www.quigleyco.com), at 10:00 AM (ET) that morning.

A replay of the conference call will be available for 30 days on the Company web site.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY) (http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture COLD-EEZE(R) lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma Inc., (
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study
2. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
3. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
4. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
5. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
6. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
7. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
8. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
9. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
10. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
11. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... Step into a macabre world where plants ... Virginia. Wicked Plants, the Museum’s latest featured exhibition, opens ... carnivorous and diabolical plants inside of a dilapidated, Victorian ... biochemical, physical and neurological processes between botanicals and the ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... have come one step closer to understanding how the ... common drugs, including some antibiotics, antihistamines and anti-psychotics, can ... estimated around 40-50% of all drugs in development will ... in the heart and, as a result, can cause ...
... Maureen Salamon HealthDay Reporter , THURSDAY, Jan. 27 ... restaurant opening in his small Louisiana town, where vacant storefronts ... Burley, an assistant professor of sociology at Southeastern Louisiana University, ... of flat-screened TVs -- one in every booth -- along ...
... , THURSDAY, Jan. 27 (HealthDay News) -- U.S. health authorities ... patients using Truvada, the once-a-day combination pill that was shown ... high-risk individuals. The guidance, from experts at the U.S. ... and bisexual men at high risk for contracting the virus ...
... unprecedented crisis in our health care system," reported J. Fred ... at today,s annual State of the Nation,s Health Care briefing. ... We have more uninsured people than ever before. We ... Health care costs are increasing at rates that the countryand ...
... Researchers from McGill University,s Rosalind and Morris Goodman Cancer ... University Health Centre (RI MUHC), the DanaFarber Cancer Institute ... that can accurately predict which breast cancer patients are ... not from the burdens associated with unnecessary treatment. ...
... stimulants tend to choose instant gratification or a smaller but ... reward is greater. Reduced value of a future reward, ... treatment of addiction. A new study in the February 2011 ... present a strategy for increasing the value of future rewards ...
Cached Medicine News:Health News:Victor Chang scientists unlock the 'gates' on sudden cardiac death 2Health News:TV: A Sneaky Part of the Food Pyramid 2Health News:TV: A Sneaky Part of the Food Pyramid 3Health News:CDC Issues Guidance on Daily Pill to Prevent Infection With HIV 2Health News:CDC Issues Guidance on Daily Pill to Prevent Infection With HIV 3Health News:ACP says Congress must find 'common ground' to address 'crisis in our health care system' 2Health News:ACP says Congress must find 'common ground' to address 'crisis in our health care system' 3Health News:Memory training explored as strategy for addiction treatment 2Health News:Memory training explored as strategy for addiction treatment 3
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Microbiology Testing/Clinical Microbiology ... - Global Forecast to 2019" report to ... a wide array of techniques for the detection ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... ... ... , , ... PHOENIX , ...
... ... ... ... ...
Cached Medicine Technology:INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 2INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 3INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 4Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 2Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 3Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 4Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 5Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 6Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 7Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 8
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: